International Journal of Phytomedicine and Phytotherapy
Table 6 Mortality as relative risk (RR) in placebo controlled cirrhosis trials
From: The potential of silymarin for the treatment of hepatic disorders
Study | Duration | Dose | Silymarin | Control | (Total mortality) | Liver Related Mortality | ||
|---|---|---|---|---|---|---|---|---|
(Weight) | (RR (fixed)) | Weight | RR (fixed) | |||||
(Mo.) | mg/day | (nt) nL/N | (nt) nL/N | (%) | (95Â % CI) | % | 95Â % CI | |
Ferenci, 1989 [115] | 24 | 420 | (28) 18/87 | (39) 31/83 | (61.79) | (0.68 [0.47, 1.00]) | 57.29 | 0.55 [0.34, 0.91] |
Trinchet,1989 [132] | 3 | 420 | (1) 01 / 57 | (3) 03 / 59 | (4.56) | (0.35 [0.04, 3.22]) | 5.32 | 0.35 [0.04, 3.22] |
Bunout,1992 [133] | 15 | 280 | (5) 04 / 34 | (5) 05 / 37 | (7.41) | (1.09 [0.34, 3.43]) | 8.65 | 0.87 [0.25, 2.98] |
Pares,1998 [116] | 24 | 450 | (16) 10/103 | (15) 14/97 | (23.91) | (1.00 [0.53, 1.92]) | 26.04 | 0.67 [0.31, 1.44] |
Lucena, 2002 [134] | 6 | 450 | (0) 0/30 | (1) 1 / 30 | (2.32) | (0.33 [0.01, 7.87]) | 2.71 | 0.33 [0.01, 7.87] |
Total (95Â % CI) | Â | Â | (50) 33/311 | (63) 54/306 | (100) | (0.77 [0.56, 1.05]) | 100 | 0.60 [0.40, 0.88] |